BR9912007A - Composições e métodos para terapia e diagnóstico de câncer de próstata - Google Patents

Composições e métodos para terapia e diagnóstico de câncer de próstata

Info

Publication number
BR9912007A
BR9912007A BR9912007-0A BR9912007A BR9912007A BR 9912007 A BR9912007 A BR 9912007A BR 9912007 A BR9912007 A BR 9912007A BR 9912007 A BR9912007 A BR 9912007A
Authority
BR
Brazil
Prior art keywords
compositions
diagnosis
methods
prostate cancer
cancer therapy
Prior art date
Application number
BR9912007-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David Clifford Dillon
Susan Louise Harlocker
Jiang Yuqiu
Jiangchun Xu
Jennifer Lynn Mitcham
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/115,453 external-priority patent/US6657056B2/en
Priority claimed from US09/116,134 external-priority patent/US7008772B1/en
Priority claimed from US09/159,812 external-priority patent/US6613872B1/en
Priority claimed from US09/232,880 external-priority patent/US7270980B2/en
Priority claimed from US09/232,149 external-priority patent/US6465611B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR9912007A publication Critical patent/BR9912007A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9912007-0A 1998-07-14 1999-07-14 Composições e métodos para terapia e diagnóstico de câncer de próstata BR9912007A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/115,453 US6657056B2 (en) 1997-02-25 1998-07-14 Compounds for immunotherapy of prostate cancer and methods for their use
US09/116,134 US7008772B1 (en) 1997-02-25 1998-07-14 Compounds for immunodiagnosis of prostate cancer and methods for their use
US15982298A 1998-09-23 1998-09-23
US09/159,812 US6613872B1 (en) 1997-02-25 1998-09-23 Compounds for immunotherapy of prostate cancer and methods for their use
US09/232,880 US7270980B2 (en) 1997-02-25 1999-01-15 Compounds for immunodiagnosis of prostate cancer and methods for their use
US09/232,149 US6465611B1 (en) 1997-02-25 1999-01-15 Compounds for immunotherapy of prostate cancer and methods for their use
US28894699A 1999-04-09 1999-04-09
PCT/US1999/015838 WO2000004149A2 (en) 1998-07-14 1999-07-14 Compositions and methods for therapy and diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
BR9912007A true BR9912007A (pt) 2002-01-29

Family

ID=27568734

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912007-0A BR9912007A (pt) 1998-07-14 1999-07-14 Composições e métodos para terapia e diagnóstico de câncer de próstata

Country Status (17)

Country Link
EP (2) EP1870466A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002520054A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20010083111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100419079C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU762812B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9912007A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2334038A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2001149A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0203035A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140845A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20010196L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509178A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL200772B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA99200618B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200100916T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW200728465A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000004149A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1007650B1 (en) 1997-04-10 2009-03-18 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, pca3 genes, and methods of use
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
CA2328989C (en) 1998-06-01 2012-02-07 Urogenesys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1169444A2 (en) * 1999-04-09 2002-01-09 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
EP1194571A1 (en) * 1999-07-13 2002-04-10 SMITHKLINE BEECHAM BIOLOGICALS s.a. Prostase vaccine
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
DK2003202T3 (da) * 1999-10-05 2012-01-16 Agensys Inc G-protein-koblet receptor opreguleret i prostatacancer og anvendelser deraf
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
WO2001025446A1 (en) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
CA2391369A1 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
CN1436234A (zh) * 2000-01-14 2003-08-13 科里克萨有限公司 用于前列腺癌治疗和诊断的组合物及方法
AU2001236782A1 (en) * 2000-02-08 2001-08-20 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CA2403909A1 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2429749A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002044418A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1515982A4 (en) * 2001-05-09 2005-10-26 Corixa Corp COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1578980A4 (en) * 2002-04-01 2013-01-02 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN 213P1F11 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
WO2003103706A2 (en) * 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions
CN100360558C (zh) * 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
PL1742966T3 (pl) 2004-04-22 2014-04-30 Agensys Inc Przeciwciała i pochodzące z nich cząsteczki, które wiążą się z białkami STEAP-1
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP1934363B1 (en) 2005-09-12 2013-03-20 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2081027A4 (en) 2006-08-04 2009-09-23 Ajinomoto Kk METHOD FOR EVALUATING LUNG CANCER, LUNG CANCER EVALUATION DEVICE, LUNG CANCER EVALUATION METHOD, LUNG CANCER EVALUATION SYSTEM, EVALUATION PROGRAM FOR A LUNG CANCER LUNG CANCER AND RECORDING MEDIUM
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
ES2387924T3 (es) 2006-10-27 2012-10-04 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
WO2008075662A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
WO2008075663A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
WO2009009431A2 (en) 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
KR100976218B1 (ko) 2008-05-26 2010-08-17 한국표준과학연구원 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표
WO2009154297A1 (ja) 2008-06-20 2009-12-23 味の素株式会社 前立腺疾患の評価方法
WO2010016525A1 (ja) * 2008-08-05 2010-02-11 東レ株式会社 免疫誘導剤
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
EP2322221B1 (en) 2008-08-05 2014-07-09 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninl Philips Electronics Nv fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PT2532366T (pt) 2010-02-04 2016-12-20 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
EP2532367B1 (en) 2010-02-04 2018-08-29 Toray Industries, Inc. Pharmaceutical agent for treatment and/or prevention of cancer
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
TW201309799A (zh) 2011-02-15 2013-03-01 Immune Design Corp 藉由載體化疫苗增強免疫原特異性免疫反應之方法
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
RU2611197C2 (ru) 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
AU2012290954B2 (en) 2011-08-04 2017-08-31 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CN103717737B (zh) 2011-08-04 2015-06-10 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
DK2824114T3 (da) 2012-02-21 2019-07-29 Toray Industries Farmaceutisk sammensætning til behandling af cancer
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
KR102005786B1 (ko) 2012-02-21 2019-07-31 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
HUE036424T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
EP3473707B1 (en) * 2012-05-25 2024-12-18 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
AU2013291047B2 (en) 2012-07-19 2018-12-06 Toray Industries, Inc. Cancer detection method
KR102110873B1 (ko) 2012-09-11 2020-05-14 온코세라피 사이언스 가부시키가이샤 Ube2t 펩티드 및 이를 포함하는 백신
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Single vial vaccine formulations
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CN108472350A (zh) * 2016-01-08 2018-08-31 瓦西博迪公司 新表位rna癌症疫苗
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
CN109195587A (zh) 2016-06-01 2019-01-11 传染病研究所 含上胶剂的纳米明矾颗粒
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
JP2022512921A (ja) * 2018-11-07 2022-02-07 アコーオス インコーポレイテッド 有毛細胞の分化を誘導する組成物及び方法
CN111000858B (zh) * 2019-05-10 2021-04-09 常州市第二人民医院 Nupr1抑制剂在制备膀胱癌治疗药物中的用途
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CN116057067A (zh) * 2020-04-17 2023-05-02 弗朗西斯·克里克研究所有限公司 用于治疗黑素瘤的ctl抗原的融合蛋白
CN111968751B (zh) * 2020-06-29 2021-10-19 金电联行（北京）信息技术有限公司 一种使用多基线校正模型的传染病趋势预测方法与系统
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
KR20230148148A (ko) 2020-12-23 2023-10-24 액세스 투 어드밴스드 헬스 인스티튜트 솔라네솔 백신 보조제 및 이의 제조 방법
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
NZ236114A (en) * 1989-11-22 1993-04-28 Merrell Dow Pharma Peptide antagonists of bombesin and of gastrin releasing peptide, and pharmaceutical compositions
CN1183104A (zh) * 1995-04-28 1998-05-27 武田药品工业株式会社 Lh－rh受体拮抗剂
AU728186B2 (en) * 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DE69831222T2 (de) * 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
TR200100916T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-06-21
HUP0203035A2 (hu) 2002-12-28
EP1870466A3 (en) 2008-03-19
SA99200618B1 (ar) 2007-01-20
NO20010196L (no) 2001-03-12
TW200532020A (en) 2005-10-01
CN1315998A (zh) 2001-10-03
KR20070112860A (ko) 2007-11-27
NO20010196D0 (no) 2001-01-12
EP1870466A2 (en) 2007-12-26
IL140845A0 (en) 2002-02-10
JP2002520054A (ja) 2002-07-09
KR20010083111A (ko) 2001-08-31
CA2334038A1 (en) 2000-01-27
WO2000004149A2 (en) 2000-01-27
AU5314899A (en) 2000-02-07
TW200728465A (en) 2007-08-01
CN100419079C (zh) 2008-09-17
NZ509178A (en) 2004-04-30
PL200772B1 (pl) 2009-02-27
EP1097208A2 (en) 2001-05-09
WO2000004149A3 (en) 2000-07-20
AU2003248213A1 (en) 2003-10-30
CZ2001149A3 (cs) 2002-02-13
AU762812B2 (en) 2003-07-03
HUP0203035A3 (en) 2007-12-28
PL346359A1 (en) 2002-02-11

Similar Documents

Publication Publication Date Title
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
AR029547A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002012332A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
YU5002A (sh) Jedinjenja i postupci za lečenje i dijagnozu raka pluća

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements